Amplification of 1q21 is associated with poor outcome after treatment with bortezomib in relapsed/refractory multiple myeloma.

被引：1
|
作者：
Drach, Johannes
Sagaster, Verena
Odelga, Victoria
Kaufmann, Hannes
Ackermann, Jutta
Galhuber, Markus
Zojer, Niklas
Kueenburg, Elisabeth
Zielinski, Christoph
Wieser, Rotraud
Ludwig, Heinz
机构：
[1] Med Univ Vienna, Dept Med 1, Div Clin Oncol, Vienna, Austria
[2] Med Univ Vienna, Inst Clin Med, Dept Human Genet, Chem Lab Diagnost, Vienna, Austria
[3] Wilhelminenspital Stadt Wien, Ctr Oncol & Hematol, Dept Med 1, Vienna, Austria
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3398.3398
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3398
引用
收藏
页码：970A / 971A
页数：2
相关论文
共 50 条
  • [1] Treatment efficacy for relapsed/refractory multiple myeloma patients with gain/amplification of 1q21
    Zhou, Xia
    Wu, Hongying
    Hao, Lumei
    Wei, Liyan
    Li, Xuemei
    Yin, Junjing
    Yu, Qianru
    Xie, Zhanzhi
    Zhong, Yuping
    CHINESE MEDICAL JOURNAL, 2025, 138 (07) : 871 - 873
  • [2] Poor prognosis associated with gain of chromosome 1Q21 in multiple myeloma may be overcome by treatment with a bortezomib combination
    Sagaster, V.
    Odelga, V.
    Kaufmann, H.
    Ackermann, J.
    Galhuber, M.
    Zojer, N.
    Ludwig, H.
    Wieser, R.
    Zielinski, C.
    Drach, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 149 - 149
  • [3] Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification
    Chang, Hong
    Trieu, Young
    Qi, Connie
    Xu, Wei
    Reece, Donna E.
    BLOOD, 2009, 114 (22) : 1104 - 1104
  • [4] Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
    Pan, Darren
    Kaufman, Jonathan L.
    Htut, Myo
    Agrawal, Manish
    Mazumder, Amitabha
    Cornell, Robert F.
    Zonder, Jeffrey A.
    Fay, Joseph W.
    Modiano, Manuel R.
    Moshier, Erin L.
    Rush, Selena A.
    Tunquist, Brian J.
    Chari, Ajai
    CANCER MEDICINE, 2022, 11 (02): : 358 - 370
  • [5] Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains
    Chang, Hong
    Trieu, Young
    Qi, Xiaoying
    Jiang, Nan N.
    Xu, Wei
    Reece, Donna
    LEUKEMIA RESEARCH, 2011, 35 (01) : 95 - 98
  • [6] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Bortezomib is cost-effective for the treatment of relapsed and refractory multiple myeloma.
    Mehta, J
    Duff, S
    Gupta, S
    BLOOD, 2003, 102 (11) : 500A - 501A
  • [8] Prognostic value of 1q21 amplification in multiple myeloma
    Abramova, T. V.
    Obukhova, T. N.
    Mendeleev, L. P.
    Pokrovskaya, O. S.
    Gribanova, E. O.
    Ryzhko, V. V.
    Grebenyuk, L. A.
    Nareyko, M. V.
    Solovyev, M. V.
    Votyakova, O. M.
    Kulikov, S. M.
    Rusinov, M. A.
    Savchenko, V. G.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 32 - +
  • [9] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Clinical synergism of Bortezomib and chemotherapy in relapsed and refractory multiple myeloma.
    Mazumder, A
    Chauvin, E
    Curran, K
    Disperati, P
    Jagannath, S
    BLOOD, 2003, 102 (11) : 390B - 390B
12345